By Fineline Cube Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two denosumab biosimilars: BA6101 (biosimilar to Amgen’s Prolia) and BA1102 (biosimilar to Amgen’s Xgeva). The applications seek approval for the full range of originator indications, positioning Boan to capture significant share in both the osteoporosis and oncology bone health markets with comprehensive therapeutic coverage across Amgen’s $6+ billion annual denosumab franchise.
Regulatory Filing Details
| Item | Detail |
|---|---|
| Company | Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) |
| Regulatory Agency | U.S. Food and Drug Administration (FDA) |
| Filing Type | Biologics License Applications (BLAs) |
| Products | BA6101 (Prolia biosimilar) and BA1102 (Xgeva biosimilar) |
| Reference Products | Amgen’s Prolia (denosumab) and Xgeva (denosumab) |
| Filing Date | 01 Jun 2026 |
| Indication Coverage | Full label extrapolation covering all originator indications |
Product Portfolio & Indications
BA6101 (Prolia Biosimilar)
- Primary Indications: Treatment and prevention of osteoporosis-related conditions
- Target Populations: Postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis
- Therapeutic Goal: Reduce fracture risk through RANK ligand inhibition
BA1102 (Xgeva Biosimilar)
- Oncology Indications:
- Bone metastases from solid tumors
- Multiple myeloma (prevention of skeletal-related events)
- Giant cell tumor of bone (unresectable or surgically challenging cases)
- Hypercalcemia of malignancy refractory to bisphosphonate therapy
- Therapeutic Goal: Prevent skeletal-related events and manage bone complications in cancer
Strategic Market Implications
Boan’s dual BLA submission addresses Amgen’s integrated denosumab franchise, which generated approximately $6.2 billion in global sales in 2025:
- Market Segmentation: Simultaneous entry into both chronic care (Prolia) and oncology (Xgeva) markets
- Pricing Strategy: Expected 30–40% cost reduction compared to originator products
- Healthcare Impact: Potential to significantly reduce U.S. healthcare system costs for bone health management
- Competitive Positioning: Among the first wave of denosumab biosimilars seeking FDA approval
“This dual BLA submission represents a major milestone in our mission to provide high-quality, affordable biologics to patients worldwide,” said Dr. Wang Li, Chief Executive Officer of Shandong Boan Biotechnology. “By addressing both osteoporosis and oncology indications with comprehensive biosimilar coverage, we aim to improve access to essential bone health therapies while generating substantial savings for the U.S. healthcare system.”
Competitive Landscape & Commercial Outlook
The U.S. denosumab biosimilar market is poised for significant disruption:
- Patent Expiry: Amgen’s key patents expired in 2025, opening the market to biosimilar competition
- Addressable Market: Combined U.S. market opportunity estimated at $3–4 billion annually
- Regulatory Pathway: FDA’s established biosimilar approval framework provides clear development requirements
- Market Access: Immediate eligibility for inclusion in pharmacy benefit manager (PBM) formularies and hospital group purchasing organization (GPO) contracts
Industry analysts expect the first denosumab biosimilars to launch in Q2–Q3 2027, with Boan well-positioned to capture significant market share given its comprehensive indication coverage and established manufacturing capabilities.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory submissions, market opportunities, and commercial expectations for BA6101 and BA1102. Actual results may differ due to FDA review outcomes, competitive dynamics, and market adoption patterns.-Fineline Info & Tech